Drug Profile

HLX 08

Alternative Names: HLX 08

Latest Information Update: 15 Feb 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Henlix Biotech
Class Monoclonal antibodies
Mechanism of Action Platelet-derived growth factor alpha receptor modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

08 Feb 2023 Discontinued - Preclinical for Solid tumours in Taiwan (Parenteral) (Shanghai Henlius Biotech pipeline, February 2023)
28 Jun 2022 No recent reports of development identified for preclinical development in Solid-tumours in Taiwan (Parenteral)
30 May 2018 Henlix Biotech plans to submit IND for HLX 08 in 2018 (Henlix Biotech pipeline May 2018)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com